Rabbit Polyclonal LDLR Antibody

Low-density lipoprotein receptor (LDLR) antibodies are tools used to study the LDLR protein, a critical player in cholesterol metabolism. LDLR, a cell-surface glycoprotein, mediates the uptake of LDL cholesterol particles into cells via endocytosis. Discovered in the 1970s, LDLR gained prominence due to its role in familial hypercholesterolemia (FH), a genetic disorder caused by LDLR mutations that impair cholesterol clearance, leading to elevated blood LDL levels and premature cardiovascular disease. Structurally, LDLR contains ligand-binding domains, epidermal growth factor (EGF) precursor homology regions, and a cytoplasmic tail for intracellular signaling. Antibodies targeting LDLR are widely used in research to detect receptor expression, localization, and function in tissues, often applied in techniques like Western blot, immunohistochemistry, and flow cytometry. They also aid in studying LDLR regulation by molecules like PCSK9. which promotes LDLR degradation. Clinically, LDLR autoantibodies are rare but have been implicated in autoimmune conditions affecting lipid metabolism. Therapeutic strategies, such as PCSK9 inhibitors, indirectly enhance LDLR availability, highlighting its importance in managing hypercholesterolemia. LDLR antibodies thus serve as vital reagents for both basic research and translational studies on cholesterol homeostasis and atherosclerosis.